Cathie Wood's ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

First demonstration of single AAV muscle editing in non-human primates: NanoCas achieved in vivo editing efficiencies of up to 30% when targeting dystrophin in the skeletal muscle of cynomolgus ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Cas enzymes are required to cut specific sections of DNA or RNA during CRISPR experiments. CRISPR is a revolutionary gene-editing tool widely used for cancer research, which is currently in the early ...